Analysts have been eager to weigh in on the Healthcare sector with new ratings on ACADIA Pharmaceuticals (ACAD), Catalyst Pharma (CPRX) and Minerva Neurosciences (NERV).
ACADIA Pharmaceuticals (ACAD)
In a report released yesterday, Sumant Kulkarni from Canaccord Genuity maintained a Hold rating on ACADIA Pharmaceuticals, with a price target of $27.00. The company’s shares closed last Tuesday at $20.84, close to its 52-week low of $19.20.
According to TipRanks.com, Kulkarni is a 4-star analyst with an average return of 14.7% and a 47.2% success rate. Kulkarni covers the Healthcare sector, focusing on stocks such as Intra-Cellular Therapies, Zynerba Pharmaceuticals, and Bioxcel Therapeutics.
ACADIA Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $32.00, a 55.0% upside from current levels. In a report issued on April 29, Oppenheimer also assigned a Hold rating to the stock with a $20.00 price target.
See today’s analyst top recommended stocks >>
Catalyst Pharma (CPRX)
H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on Catalyst Pharma today and set a price target of $9.00. The company’s shares closed last Tuesday at $4.74.
According to TipRanks.com, Fein is a 5-star analyst with an average return of 13.9% and a 47.8% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Constellation Pharmaceuticals, and Global Blood Therapeutics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Catalyst Pharma with a $7.17 average price target, which is a 57.6% upside from current levels. In a report released yesterday, Piper Sandler also maintained a Buy rating on the stock with a $5.50 price target.
Minerva Neurosciences (NERV)
In a report released today, Douglas Tsao from H.C. Wainwright maintained a Buy rating on Minerva Neurosciences, with a price target of $10.00. The company’s shares closed last Tuesday at $2.23, close to its 52-week low of $1.81.
According to TipRanks.com, Tsao is a 4-star analyst with an average return of 13.5% and a 48.8% success rate. Tsao covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, Crinetics Pharmaceuticals, and Protagonist Therapeutics.
Currently, the analyst consensus on Minerva Neurosciences is a Moderate Buy with an average price target of $9.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
